alexa Efficacy Of Different Regimens Of Intraperitoneal Chemoperfusions With Cisplatin In A Rat Model Of Ovarian Cancer Peritoneal Carcinomatosis
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd World Congress on Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

V. G. Bespalov, O. A. Belyaeva, A. N. Stukov, K. Yu. Senchik, G. S. Kireeva and V. A. Aristova
Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.030
Abstract
Currently hyperthermic intraperitoneal chemoperfusion (HIPEC) becomes an important part of peritoneal carcinomatosis treatment in patients with ovarian cancer. Cisplatin is commonly used at this treatment; however doses of the drug and chemoperfusion regimens are discussed. Comparative study of HIPEC and normothermal intraperitoneal chemotherapy (IPEC) with high-doses of cisplatin in a rat model of ovarian cancer peritoneal carcinomatosis was our purpose. Ovarian cancer cells were inoculated intraperitoneally (i.p.) in 99 Wistar female rats. We used cisplatin 48 hours after the i.p. tumor inoculation in maximal tolerable doses of 4 mg/kg for i.p. injection, 40 mg/kg for IPEC, and 20 mg/kg for HIPEC. In the rats of control group saline solution was administered i.p. at a volume of 0.5 ml. The antitumor effect of cisplatin was estimated by increasing median survival time (MST). In the control group MST was 9.0 days. Single i.p. injection of cisplatin increased MST by 116% (MST=19.5, p=0.008) compared with the control group. IPEC and HIPEC with cisplatin increased MST by 317% (MST=37.5, p<0.001) and by 183% (MST=25.5, p<0,003), correspondingly, compared with the control group. In comparison with IPEC without drug (MST=16.0) IPEC with cisplatin increased MST by 134% (p=0,002). Thus cisplatin administered with intraperitoneal chemoperfusions had the most significant cytostatic effects; however at IPEC regimen cisplatin had higher maximal tolerable dose and antitumor activity than at HIPEC regimen. IPEC with cisplatin may be more effective and less toxic than HIPEC with the drug and further clinical trials of these treatment regimens are warranted in ovarian cancer patients.
Biography
V. G. Bespalov, is as Doctor of Medical Sciences, Head of Laboratory of Cancer Chemoprevention and Oncopharmacology, has been working in the N.N. Petrov Research Institute of Oncology during 30 years. He is member of an administrative Academic Council and a dissertational Academic Council of the N.N. Petrov Research Institute of Oncology, member of the Russian Oncological Society and the Russian Oncourological Society, scientific editor of Russian medical journals. He has published more than 130 papers in reputed journals and 20 monographies and books on the topics of cancer prevention, cancer chemoprevention, cancer chemotherapy, treatment of precancerous diseases, dietology and rehabilitation.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords